Marc Goodman
Stock Analyst at Leerink Partners
(2.91)
# 1,584
Out of 4,876 analysts
96
Total ratings
55.56%
Success rate
26.51%
Average return
Main Sectors:
Stocks Rated by Marc Goodman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMLX Amylyx Pharmaceuticals | Upgrades: Outperform | $4 → $10 | $6.44 | +55.28% | 5 | May 7, 2025 | |
| OPT Opthea | Downgrades: Market Perform | $12 → $1 | $3.41 | -70.67% | 2 | Mar 25, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $110 → $150 | $105.63 | +42.01% | 7 | Feb 10, 2025 | |
| RLMD Relmada Therapeutics | Downgrades: Market Perform | $10 → $1 | $0.66 | +52.44% | 3 | Dec 4, 2024 | |
| BHVN Biohaven | Maintains: Outperform | $55 → $60 | $14.52 | +313.22% | 6 | Sep 23, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Outperform | $32 | $30.00 | +6.67% | 1 | Apr 15, 2024 | |
| BLTE Belite Bio | Initiates: Outperform | $25 | $60.68 | -58.80% | 1 | Jul 26, 2023 | |
| DNLI Denali Therapeutics | Initiates: Outperform | $50 | $14.26 | +250.63% | 1 | Jan 30, 2023 | |
| EOLS Evolus | Maintains: Outperform | $18 → $20 | $9.26 | +115.98% | 3 | Jan 19, 2023 | |
| NBIX Neurocrine Biosciences | Maintains: Market Perform | $100 → $115 | $126.64 | -9.19% | 4 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $310 | $127.18 | +143.75% | 11 | Oct 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $12 | $9.13 | +31.43% | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $46 | $32.26 | +42.61% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $21 | $22.25 | -5.62% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $210 | $108.55 | +93.46% | 5 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $50 → $40 | $9.27 | +331.73% | 5 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $2.05 | +387.80% | 2 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $24 → $27 | $28.87 | -6.48% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $15 | $3.89 | +285.60% | 2 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $270 | $458.85 | -41.16% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $79 → $96 | $186.12 | -48.42% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $46.79 | - | 2 | May 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $67 | $78.93 | -15.11% | 3 | Oct 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $98 | $26.69 | +267.18% | 7 | Oct 5, 2017 |
Amylyx Pharmaceuticals
May 7, 2025
Upgrades: Outperform
Price Target: $4 → $10
Current: $6.44
Upside: +55.28%
Opthea
Mar 25, 2025
Downgrades: Market Perform
Price Target: $12 → $1
Current: $3.41
Upside: -70.67%
Axsome Therapeutics
Feb 10, 2025
Maintains: Outperform
Price Target: $110 → $150
Current: $105.63
Upside: +42.01%
Relmada Therapeutics
Dec 4, 2024
Downgrades: Market Perform
Price Target: $10 → $1
Current: $0.66
Upside: +52.44%
Biohaven
Sep 23, 2024
Maintains: Outperform
Price Target: $55 → $60
Current: $14.52
Upside: +313.22%
LENZ Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: $32
Current: $30.00
Upside: +6.67%
Belite Bio
Jul 26, 2023
Initiates: Outperform
Price Target: $25
Current: $60.68
Upside: -58.80%
Denali Therapeutics
Jan 30, 2023
Initiates: Outperform
Price Target: $50
Current: $14.26
Upside: +250.63%
Evolus
Jan 19, 2023
Maintains: Outperform
Price Target: $18 → $20
Current: $9.26
Upside: +115.98%
Neurocrine Biosciences
Nov 2, 2022
Maintains: Market Perform
Price Target: $100 → $115
Current: $126.64
Upside: -9.19%
Oct 26, 2022
Maintains: Outperform
Price Target: $270 → $310
Current: $127.18
Upside: +143.75%
Aug 11, 2022
Maintains: Outperform
Price Target: $6 → $12
Current: $9.13
Upside: +31.43%
Aug 11, 2022
Maintains: Outperform
Price Target: $40 → $46
Current: $32.26
Upside: +42.61%
Aug 9, 2022
Maintains: Outperform
Price Target: $27 → $21
Current: $22.25
Upside: -5.62%
Aug 4, 2022
Maintains: Outperform
Price Target: $200 → $210
Current: $108.55
Upside: +93.46%
Jul 11, 2022
Maintains: Market Perform
Price Target: $50 → $40
Current: $9.27
Upside: +331.73%
Jul 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $2.05
Upside: +387.80%
Apr 28, 2022
Maintains: Market Perform
Price Target: $24 → $27
Current: $28.87
Upside: -6.48%
Dec 21, 2021
Maintains: Outperform
Price Target: $24 → $15
Current: $3.89
Upside: +285.60%
Mar 13, 2020
Maintains: Buy
Price Target: $300 → $270
Current: $458.85
Upside: -41.16%
Nov 19, 2019
Maintains: Buy
Price Target: $79 → $96
Current: $186.12
Upside: -48.42%
May 21, 2018
Downgrades: Neutral
Price Target: n/a
Current: $46.79
Upside: -
Oct 30, 2017
Maintains: Buy
Price Target: $72 → $67
Current: $78.93
Upside: -15.11%
Oct 5, 2017
Maintains: Buy
Price Target: $84 → $98
Current: $26.69
Upside: +267.18%